Haemate P (Human Coagulation Factor Viii, Human Von Willebrand Factor)

Haemate P is a prescription solution for injection that contains human coagulation factor VIII and human von Willebrand factor. It is supplied as a sterile liquid concentrate without a specified strength, intended for intravenous administration. The product is used in the European market to replace deficient clotting factors in patients with hemophilia A or von Willebrand disease, helping to support normal blood clot formation.

Haemate P is indicated for the management of bleeding episodes and perioperative prophylaxis in patients with specific clotting disorders. It is used under medical supervision to replace missing clotting proteins.

- Treatment of acute bleeding episodes in hemophilia A patients. - Surgical or invasive procedure prophylaxis for hemophilia A. - Management of bleeding in von Willebrand disease types 1, 2, and 3. - Long‑term prophylaxis to reduce frequency of spontaneous bleeds in severe hemophilia A. - Adjunct therapy when other factor concentrates are unavailable or contraindicated.

Side effects of Haemate P may vary in frequency and severity. Patients should be monitored for any adverse reactions during and after infusion.

Common: - Headache or mild dizziness. - Fever or chills. - Injection site pain, redness, or swelling. - Nausea or mild gastrointestinal discomfort. - Transient increase in blood pressure.

Serious: - Development of inhibitors (antibodies) against factor VIII. - Allergic reactions including rash, urticaria, or anaphylaxis. - Thromboembolic events such as deep vein thrombosis. - Hemolysis or renal impairment. - Severe hypotension or shock.

Healthcare providers should assess individual risk factors before initiating Haemate P therapy. Monitoring and patient education are essential.

- Screen for a history of inhibitors to factor VIII before treatment. - Use caution in patients with cardiovascular disease or a history of thrombosis. - Monitor for signs of allergic reactions during infusion. - Adjust dosing in patients with renal or hepatic impairment as clinically indicated. - Ensure proper aseptic technique to prevent contamination. - Educate patients on recognizing symptoms of inhibitor development and thrombosis.

Haemate P may interact with other medications that affect hemostasis or immune response. Review patient medication lists carefully.

Avoid: - Concurrent use of pro‑coagulant agents (e.g., activated prothrombin complex concentrates) without specialist guidance. - High‑dose aspirin or non‑steroidal anti‑inflammatory drugs (NSAIDs) that increase bleeding risk.

Use with caution: - Immunosuppressive therapies that may alter inhibitor formation. - Antifibrinolytic agents (e.g., tranexamic acid) when combined with factor replacement. - Other plasma‑derived products that could increase viral transmission risk. - Vaccinations administered shortly before or after infusion.